FMC Q2 revenue down 17% to $867M, GAAP loss $1.49/share; lowers full-year guidance

FMC CORP

Q2 revenue $867M (-17% YoY); GAAP net loss $187M ($1.49 loss per share); adjusted EPS $0.26 (-62%).
Adjusted EBITDA $153M (-26% YoY); cash from ops $363M including $200M rimisoxafen licensing payment.
Full-year 2026 outlook lowered: revenue ex-India $3.50B-$3.70B, Adj. EBITDA $620M-$680M, Adj. EPS $1.19-$1.49.
Strategic actions: India sale ($252M), rimisoxafen licensing ($200M), Newark sale-leaseback ($114M), Tessenderlo equity ($400M) – ~$1B for debt reduction.
Board concludes strategic review; Q3 Adj. EBITDA guided $120M-$140M, Q4 $275M-$315M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.